February 20, 2025 argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
December 27, 2024 argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
Follow us
Get the latest news and info via our social media channels.